Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electrophoresis, Gel, Two-Dimensional | 4 | 2009 | 39 | 0.380 |
Why?
|
| Proteomics | 4 | 2014 | 283 | 0.340 |
Why?
|
| Proteome | 3 | 2014 | 150 | 0.340 |
Why?
|
| Piperazines | 1 | 2008 | 81 | 0.280 |
Why?
|
| Pyrimidines | 1 | 2008 | 137 | 0.270 |
Why?
|
| Ovarian Neoplasms | 1 | 2008 | 150 | 0.260 |
Why?
|
| Colon | 1 | 2007 | 147 | 0.240 |
Why?
|
| Colorectal Neoplasms | 1 | 2007 | 276 | 0.210 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 663 | 0.190 |
Why?
|
| Proteins | 1 | 2007 | 750 | 0.180 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 153 | 0.150 |
Why?
|
| Wounds and Injuries | 1 | 2020 | 246 | 0.130 |
Why?
|
| Mucins | 2 | 2014 | 27 | 0.120 |
Why?
|
| Cerebral Revascularization | 1 | 2015 | 30 | 0.120 |
Why?
|
| Endarterectomy, Carotid | 1 | 2015 | 91 | 0.110 |
Why?
|
| Calgranulin A | 1 | 2014 | 5 | 0.110 |
Why?
|
| Calgranulin B | 1 | 2014 | 6 | 0.110 |
Why?
|
| Blood Proteins | 1 | 2013 | 76 | 0.100 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 147 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2015 | 218 | 0.100 |
Why?
|
| Mass Spectrometry | 2 | 2014 | 301 | 0.090 |
Why?
|
| Registries | 1 | 2015 | 893 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 341 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 508 | 0.080 |
Why?
|
| Cyst Fluid | 1 | 2009 | 5 | 0.080 |
Why?
|
| Pancreatic Cyst | 1 | 2009 | 24 | 0.080 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2008 | 8 | 0.070 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2008 | 8 | 0.070 |
Why?
|
| Imatinib Mesylate | 1 | 2008 | 34 | 0.070 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2008 | 18 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 42 | 0.070 |
Why?
|
| Methotrexate | 1 | 2008 | 80 | 0.070 |
Why?
|
| Benzamides | 1 | 2008 | 65 | 0.070 |
Why?
|
| Catalase | 1 | 2007 | 23 | 0.070 |
Why?
|
| Glutathione Transferase | 1 | 2007 | 41 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 207 | 0.070 |
Why?
|
| Stroke | 1 | 2015 | 1196 | 0.060 |
Why?
|
| Superoxide Dismutase | 1 | 2007 | 225 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 770 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 1471 | 0.050 |
Why?
|
| Humans | 9 | 2020 | 63511 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2020 | 288 | 0.040 |
Why?
|
| Female | 4 | 2015 | 32912 | 0.030 |
Why?
|
| United States | 2 | 2020 | 7852 | 0.030 |
Why?
|
| Pancreatic Juice | 1 | 2014 | 1 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 36 | 0.030 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2014 | 31 | 0.030 |
Why?
|
| Peptide Mapping | 1 | 2013 | 29 | 0.030 |
Why?
|
| Carcinoma in Situ | 1 | 2014 | 35 | 0.030 |
Why?
|
| Reference Standards | 1 | 2013 | 73 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2015 | 204 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 127 | 0.030 |
Why?
|
| Middle Aged | 4 | 2015 | 17644 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2015 | 228 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 216 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 1230 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 422 | 0.020 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2014 | 111 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 5474 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 346 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1380 | 0.020 |
Why?
|
| Stents | 1 | 2015 | 502 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 1147 | 0.020 |
Why?
|
| Adult | 3 | 2015 | 16837 | 0.020 |
Why?
|
| Male | 4 | 2015 | 29927 | 0.020 |
Why?
|
| Amylases | 1 | 2009 | 12 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2009 | 33 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 1749 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 84 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2009 | 182 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 1655 | 0.020 |
Why?
|
| Genes, APC | 1 | 2008 | 10 | 0.020 |
Why?
|
| Leucovorin | 1 | 2008 | 9 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2009 | 131 | 0.020 |
Why?
|
| Antidotes | 1 | 2008 | 21 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 58 | 0.020 |
Why?
|
| Lymphoma, B-Cell | 1 | 2008 | 61 | 0.020 |
Why?
|
| Rituximab | 1 | 2008 | 88 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2008 | 265 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 191 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 206 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 612 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2008 | 298 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2008 | 242 | 0.020 |
Why?
|
| Aged | 2 | 2015 | 14472 | 0.020 |
Why?
|
| Sex Factors | 1 | 2008 | 978 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2008 | 310 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 449 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 1561 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 865 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2009 | 3301 | 0.010 |
Why?
|
| Mutation | 1 | 2008 | 2614 | 0.010 |
Why?
|
| Adolescent | 1 | 2008 | 6248 | 0.010 |
Why?
|